Daiichi Sankyo Vanflyta gets US FDA nod for patients with newly diagnosed FLT3-ITD positive AML Ruchika Sharma23 July 2023 12:00 PM ISTTokyo: Daiichi Sankyo has announced that VANFLYTA (quizartinib) has been approved by the U.S. Food and Drug Administration (FDA) in combination with...
AstraZeneca, Daiichi Sankyo gets Chinese nod for Enhertu as first HER2-directed therapy for patients with HER2-low metastatic breast cancer Ruchika Sharma16 July 2023 1:00 PM ISTEnhertu is a HER2-directed ADC.
Kite announces completion of marketing authorization transfer for Yescarta CAR T-cell therapy in Japan Ruchika Sharma25 Jun 2023 2:30 PM ISTSanta Monica: Kite Pharma, Inc., a Gilead Company, has announced that the Marketing Authorization in Japan for Yescarta (axicabtagene...
DCGI okays AstraZeneca's breast cancer drug Trastuzumab deruxtecan Ruchika Sharma4 May 2023 12:41 PM ISTThe HER2 is a tyrosine kinase receptor growth-promoting protein expressed on the surface of multiple tumours including breast, gastric, lung and...
Delhi HC permits Daiichi Sankyo to withdraw over Rs 20.5 crore deposited with court Ruchika Sharma26 April 2023 12:30 PM ISTNew Delhi: The Delhi High Court Monday permitted Japanese pharma major Daiichi Sankyo to withdraw over Rs 20.5 crore which was transmitted to the high...
USFDA extends review period for Daiichi Sankyo acute myeloid leukemia drug Quizartinib Ruchika Sharma23 April 2023 4:00 PM ISTQuizartinib is an oral, highly potent type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for...
AstraZeneca Enhertu shows clinically meaningful, durable responses across multiple HER2-expressing tumour types in DESTINY-PanTumor02 Phase II trial Ruchika Sharma8 March 2023 1:00 PM ISTHER2 is a tyrosine kinase receptor protein expressed on the surface of various tissue cells throughout the body and is involved in normal cell growth.
AstraZeneca-Daiichi Sankyo Enhertu approved in China for breast cancer Ruchika Sharma25 Feb 2023 1:30 PM ISTUK: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in China as a monotherapy for the treatment of adult...
Daiichi Sankyo submits application for marketing approval of mRNA COVID vaccine DS-5670 in Japan Ruchika Sharma15 Jan 2023 9:00 AM ISTTokyo: Daiichi Sankyo has announced the submission of an application for marketing approval of DS-5670 to the regulatory authorities in Japan.DS-5670...
Daiichi Sankyo unveils Blood cancer drug EZHARMIA in Japan Ruchika Sharma21 Dec 2022 4:00 PM ISTAdult T-cell leukemia-lymphoma (abbreviated ATLL or ATL) is a rare and aggressive hematologic malignancy that is caused by human T-cell lymphotropic...
Kite Pharma, Daiichi Sankyo revise YESCARTA CAR T-Cell Therapy licensing agreement Ruchika Sharma11 Dec 2022 2:15 PM ISTTokyo: Kite Pharma, Inc., a Gilead Company, (hereafter Kite), and Daiichi Sankyo Co., Ltd. have jointly announced the revision of their 2017...
Experts say patient selection for AstraZeneca, Daiichi breast cancer drug needs improvement Ruchika Sharma10 Dec 2022 1:30 PM ISTUK: The rush to use AstraZeneca and Daiichi-Sankyo's drug Enhertu to treat certain types of breast cancer has far outpaced doctors' ability to...
